RT Journal Article SR Electronic T1 68Ga-PSMA PET/CT impact on prostate cancer management JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP jnumed.117.192625 DO 10.2967/jnumed.117.192625 A1 Asim Afaq A1 Suliman Alahmed A1 Shih-hsin Chen A1 Thabo Lengana A1 Athar Haroon A1 Heather Payne A1 Hashim Ahmed A1 Shonit Punwani A1 Mike Sathekge A1 Jamshed Bomanji YR 2017 UL http://jnm.snmjournals.org/content/early/2017/07/26/jnumed.117.192625.abstract AB Aim: To assess the impact of 68Ga-Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography/ Computed Tomography (PET/CT) on management of prostate cancer in patients with biochemical recurrence (BCR). Methods: Documented management plans were retrospectively reviewed before and after 68Ga-PSMA PET/CT in 100 patients with BCR and change in plans recorded. Results: Management changed after 68Ga-PSMA PET/CT in 39 patients (39%). These occurred in 23/68 (33.8%) of patients with radical prostatectomy (RP) and 16/32 (50%) of patients previously treated with radical radiotherapy. Positive scan (P < 0.001) and higher Prostate Specific Antigen (PSA) (P = 0.024) were associated with management changes. No significant association with management change was found with Gleason grade, stage, presence of metastatic disease, PSA velocity or doubling time. Conclusion: 68Ga-PSMA PET/CT altered management in 39% of patients with BCR, and occurred more often in patients with radical radiotherapy treatment, a positive 68Ga-PSMA scan and higher PSA level.